Condition
Glabellar Furrowing
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06448676Phase 4Recruiting
Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides
NCT00611273Phase 4CompletedPrimary
A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing
NCT00612378Not ApplicableCompletedPrimary
A Multi-center Acute Efficacy Trial of GFX For Reduction of Glabellar Furrowing
Showing all 3 trials